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Abstract. Fear of adverse events (AEs) negatively affects compliance to mass drug administration (MDA) for lymphatic
ﬁlariasis (LF) elimination program. Systemic AEs are believed to occur because of killing of microﬁlariae, whereas localized
soft tissue reactions might be due to the death of adult worms following therapy. Most AEs are mild and self-limited.
However, localized AEs are sometimes more signiﬁcant and of concern to participants. Here, we describe localized AEs
that were noted during a large community study that evaluated the safety of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) for the treatment of LF in India. We have also discussed the importance of timely
detection and careful management of AEs for preserving community conﬁdence in MDA.

participants were evaluated in their homes by medical teams
during active follow-up on day 1 and 2 after treatment. The
overall AE rate in the 7 days post-treatment was 7.1%, and the
vast majority of these AEs were mild systemic events, such as
headache, fever, and myalgia.6 Eight participants (0.08%)
experienced localized AEs in the week following treatment.

The WHO has adopted annual mass drug administration
(MDA) with single-dose diethylcarbamazine (DEC) and
albendazole as the principal strategy for lymphatic ﬁlariasis
(LF) elimination in areas where onchocerciasis is not coendemic.1 Yearly MDA for 5 years with 65% compliance is recommended for successful elimination. Fear of adverse events
(AEs) and rumors about such events can signiﬁcantly decrease MDA compliance and efﬁcacy.2 Recently, a triple-drug
regimen (ivermectin plus DEC and albendazole, IDA) has been
reported to be more effective than DEC plus albendazole (DA)
for clearing microﬁlaremia (Mf).3,4 We conducted a study in an
LF-endemic area in South India to evaluate the safety, efﬁcacy, and effectiveness of IDA and DA when these medications were provided as MDA in communities.5,6 Here, we
describe a series of localized AEs that occurred during this
study and discuss their signiﬁcance.
An open-label, block-randomized, controlled trial was carried out in six villages in Yadgir district, Karnataka, India, as
part of a ﬁve-country multicenter study. Details regarding that
study have been recently published.6 The study villages were
endemic for bancroftian ﬁlariasis. Although the area had received MDA for 13 years, compliance had been suboptimal.
Enrolled participants were tested with Alere™ Filariasis Test
Strip (FTS) for ﬁlarial antigenemia. Persons with positive antigen tests had night blood testing for Mf (60-μL-thick smear).
Participants were administered (irrespective of infection status) either DA or IDA according to their village of residence.
Participants were actively assessed for AEs by medical teams
for 2 days, and passive follow-up was continued for another
5 days. Follow-up studies to assess the efﬁcacy of these
treatments in infected individuals and the impact of MDA on
LF prevalence in the study villages will be reported separately.
The study was approved by the Institute Human Ethics
Committee of the ICMR-Vector Control Research Centre in
Puducherry, India, and the trial was registered with the Clinical
Trial Registry India-CTRI/2016/10/007399.5
Baseline antigenemia and Mf prevalence in the study area
were 25.3% and 6.3%, respectively. A total of 9,060 participants were provided either DA or IDA, and of these, 98.7% of

CASE DESCRIPTIONS
Transient lymphedema. A 13-year-old girl (FTS positive,
Mf negative) developed swelling and pain in her left inguinal
region 4 days after treatment with DA. Two days later, she
noticed swelling of her left ankle and the dorsal aspect of her
left foot, and pitting edema was present (Figure 1). Tender leftsided inguinal lymphadenopathy was still present at that time.
There was no history of trauma. She had no redness or pain
over the leg and no other symptoms. She was reassured,
advised to elevate her left leg at night, and instructed on exercises to improve lymphatic drainage. The child was also
treated with diclofenac/ranitidine for 1 week. She was observed by our medical team periodically at home, and her

FIGURE 1. A 13-year-old girl developed edema of her left ankle and
the dorsum of her left foot approximately 1 week after treatment with
diethylcarbamazine plus albendazole. This ﬁgure appears in color at
www.ajtmh.org.
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FIGURE 2. Resolution of the left foot and ankle edema one month
after treatment. This ﬁgure appears in color at www.ajtmh.org.

family members were reassured. Her lymphadenitis subsided
after one additional week and her edema resolved fully after
1 month (Figure 2). The girl was revaluated 1 year later. Her leg
and inguinal area were normal; her ﬁlarial antigen test
remained positive, but her Mf test was negative. She was retreated with IDA at that time and followed up for 1 month. No
AEs were observed.
Scrotal swelling. Details for participants who developed
testicular swelling are provided in Table 1.
Skin nodules/subcutaneous swellings. Case 1. A 25year-old woman noticed a small nodule in the right arm above
the elbow 7 days after DA treatment. Her FTS test was positive
but Mf was absent. Swelling was nonprogressive but painful.
She reported her problem to the ﬁeld medical team 12 days
after treatment. Two nodules measuring 1 cm in diameter were
present on the outer aspect of the right arm. There was no
axillary lymphadenopathy. She did not have other AEs. She
was treated with diclofenac/ranitidine for 1 week. Swelling
resolved after 2 weeks. One year later, her arm was normal;
she was still FTS positive and Mf negative.

Case 2. A 30-year-old woman developed fever, nausea,
vomiting, and abdominal pain the day after IDA treatment. Her
FTS test was strongly positive, and she had 36 Mf per 60 μL.
She had a tender subcutaneous nodule on the left arm, 2 cm
below the deltoid tuberosity. She was treated with paracetamol, diclofenac, ranitidine, and ondansetron. She became
afebrile the next day and vomiting also subsided. Diclofenac
and ranitidine were continued for another 5 days. She was
followed up by a medical team at her home regularly, and
swelling disappeared after 2 weeks. She refused testing and
re-treatment when she was visited 1 year later.
Case 3. A 14-year-old girl developed fever the night after
IDA treatment. Her FTS test was strongly positive and she had
4 Mf per 60 μL. She noted tender swelling over her right
forearm 2 days later. There was no lymphadenitis. She was
treated with paracetamol, diclofenac, and ranitidine. Pain and
fever resolved after 3 days. Diclofenac and ranitidine were
continued for another 3 days. The swelling resolved over a
period of 1 week. One year later, her FTS result was still positive but her Mf test was negative.
Lymphadenitis. Case 1. A 35-year-old woman developed
pain and swelling in her left axilla with a tender 1-cm palpable
lymph node 2 days after treatment with IDA. Her FTS test was
positive, but her Mf test was negative. On day 4 after treatment, she noted tenderness and 3- by 2-cm area of induration
over the medial aspect of her left forearm, 3 cm below the
elbow. She was reassured and treated with diclofenac and
ranitidine for 1 week, and both the swellings resolved. Her arm
was normal and her FTS test was negative 1 year after IDA
treatment.
Case 2. Inguinal lymphadenitis was present in the girl with
leg edema, as aforementioned.
DISCUSSION
Systemic reactions (fever/headache/myalgia) and localized
reactions (skin nodules/breast and scrotal swellings) have
been reported following the treatment of ﬁlariasis with DEC or
with other drugs.7–11 Systemic AEs are believed to be caused
by host responses to dying Mf and localized reactions, by host
responses to dead/dying adult ﬁlarial worms.7,12
Limb swelling following MDA similar to our case has been
reported previously.8–10 However, clinical details, treatment
provided, and long-term outcome were not reported. Two

TABLE 1
Details of cases with scrotal swelling
Case No.

Age (years)
Drug regimen
FTS test
Mf test
Clinical features
Duration (days)
Treatment
Follow-up after
1 year
FTS test
Mf test

Case 1

Case 2

Case 3

24
Double-drug therapy (DA)
Strong positive
4 per 60 μL
Pain and swelling of the right testicle on
day 2 after treatment. Participant was
anxious and stressed
7
Reassurance and treatment with
diclofenac and ranitidine

26
Triple-drug therapy (IDA)
Strong positive
1 per 60 μL
Pain and swelling of the right testicle 5
days after treatment

24
Triple-drug therapy (IDA)
Strong positive
7 per 60 μL
Fever, headache, body ache, pain, and
swelling of the right testicle on day 2
after treatment
10
Reassurance and treatment with
paracetamol, diclofenac, and
ranitidine

Strong positive
Negative

Strong positive
Negative

FTS = Filariasis Test Strips; Mf = microﬁlaremia.

7
Reassurance and treatment with
diclofenac and ranitidine

Strong positive
Negative
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studies documented reversal of lymphatic pathology following single-dose treatment with DEC plus albendazole in children infected with ﬁlarial worms.13,14 None of the participants
in those studies developed new onset lymphedema or soft
tissue reactions. Scrotal pain and swelling are well recognized
but uncommon AEs following LF treatment. This appears to be
especially common after prolonged treatment with high doses
of albendazole.15,16 Prior studies/reviews have also documented the occurrence of post-treatment subcutaneous
nodules and lymphangitis.12,17
Managing AEs in village communities poses unique challenges. People often consider AEs to be the direct effect of
drugs, and it can be difﬁcult to convince them that the AEs
result from death of ﬁlarial worms. Rumors can quickly spread
and decrease compliance with MDA. Community trust was a
challenge for our study, as the region had already received
MDA for many years with poor compliance and villagers had
many misconceptions. Relatives of participants who experienced AEs reacted harshly, and sometimes their neighbors
refused to participate. Often, illiterate villagers abused the
staff and threatened violence. There is no shortcut for establishing trust in a community. However, our close cooperation
with local health ofﬁcials/village leaders and careful management of AEs improved the situation over time.
Community preparation with various IEC (information/
education/communication) activities by our dedicated medical social workers and formation of community advisory
boards comprising local leaders/village representatives/
health staff to oversee study activities were helpful in gaining
community trust. We provided a highly visible and wellequipped rapid response medical team with a hotline mobile
telephone to respond to AE reports. Study staff were
acquainted with the local culture, and care was taken to avoid
panic and not to overreact to adversity. We preferred to
manage AEs in participants’ home whenever possible rather
than moving them to the local health center/hospital. Immediate management of AEs, good counseling, repeated home
visits by our staff, and engagement of community leaders
were crucial for ensuring participants’ conﬁdence. Frequent
and appropriate brieﬁng of mass media (including social media) can help to curtail the spread of rumors regarding AEs.
The WHO has published guidelines addressing practical
aspects of prevention/detection/management of serious AEs
that occur following preventive chemotherapy programs (including MDA).18 Tanzania has adopted a modiﬁed version of
these guidelines according to conditions speciﬁc to their
country.19 As India is considering the use of IDA for LF elimination in speciﬁc situations, this is the right time for developing
a preventive chemotherapy safety surveillance component in
the program that will improve compliance and prevent misconceptions regarding MDA.
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